Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 6/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 6/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8044285 | 0.87 | HDAC1 (0.43) | TP53HDAC1HDAC8HDAC6LMNA | |
| SCHEMBL3662029 | 0.86 | PRSS1 (0.42) | PRSS1PRSS2PRSS3POLBMAOA | |
| SCHEMBL3654964 | 0.84 | PRSS1 (0.42) | PRSS1PRSS2PRSS3POLBMAOA | |
| SCHEMBL2110718 | 0.81 | SMN1; SMN2 (0.49) | TP53HDAC1HDAC8HDAC6LMNA | |
| SCHEMBL8051490 | 0.81 | POLB (0.42) | PRSS1PRSS2PRSS3POLBLMNA | |
| SCHEMBL3678665 | 0.81 | PRSS1 (0.68) | PRSS1PRSS2PRSS3MAOAMAOB | |
| SCHEMBL13830388 | 0.80 | PRSS1 (0.46) | HDAC1HDAC8HDAC6PRSS1PRSS2 | |
| SCHEMBL3438853 | 0.79 | PRSS1 (0.47) | HDAC1HDAC8HDAC6PRSS1PRSS2 | |
| SCHEMBL2109867 | 0.78 | PRSS1 (0.58) | PRSS1PRSS2PRSS3MAOAMAOB | |
| SCHEMBL14898228 | 0.78 | PRSS1 (0.42) | HDAC1PRSS1PRSS2PRSS3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536189-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2009067202-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | TP53 4763/4885HDAC1 1025/4885HDAC8 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.